Top Cagrilintide Studies — Clinical Trial Results | Real Peptides

Top cagrilintide studies published between 2021 and 2025 consistently demonstrate something the early GLP-1 trials never achieved: dual-receptor activation that targets both amylin and calcitonin pathways simultaneously, producing mean body weight reductions of 10.8–15.1% across multiple Phase 2 cohorts. The mechanism matters. Cagrilintide doesn't just suppress appetite; it physically slows gastric emptying through amylin receptor activation in the area postrema while simultaneously reducing osteoclast activity via calcitonin receptor binding, creating a metabolic effect profile that monotherapy GLP-1 agonists can't replicate.

Our team has followed the development of cagrilintide since Novo Nordisk first disclosed preclinical amylin data in 2018. The gap between what the early trials suggested and what combination therapy trials later proved is exactly the kind of insight that matters when sourcing research-grade peptides for metabolic studies.

What are the top cagrilintide studies and what do they show?

The top cagrilintide studies. Primarily Phase 2 RCTs published in The Lancet and Diabetes, Obesity and Metabolism between 2021 and 2025. Demonstrate that cagrilintide 2.4mg weekly combined with semaglutide 2.4mg produces mean body weight reductions of 15.1% at 20 weeks versus 9.2% with semaglutide alone. The mechanism driving this difference is amylin-mediated gastric emptying delay, which extends meal-to-meal satiety beyond what GLP-1 receptor activation alone can achieve. These trials established cagrilintide as the first long-acting amylin analogue to reach late-stage human testing for obesity.

Most overviews of cagrilintide frame it as 'another GLP-1 alternative'. That fundamentally misrepresents the pharmacology. Cagrilintide is an amylin receptor agonist, not a GLP-1 mimetic. The confusion arises because both pathways influence satiety, but the mechanisms are distinct: GLP-1 acts centrally in the hypothalamus to reduce hunger signaling, while amylin acts peripherally in the brainstem to slow gastric motility and delay nutrient absorption. This article covers the five landmark trials that define cagrilintide's clinical profile, the precise mechanism that differentiates it from semaglutide and tirzepatide, and what early-stage metabolic researchers should know about sourcing high-purity amylin analogues before regulatory approval.

What the Phase 2 Monotherapy Trial Revealed About Dose-Response Relationships

The 2021 Diabetes, Obesity and Metabolism monotherapy trial (NCT03667586) tested cagrilintide as a standalone treatment across five ascending doses. 0.3mg, 0.6mg, 1.2mg, 2.4mg, and 4.5mg. Administered subcutaneously once weekly for 26 weeks in 706 adults with obesity (BMI 30–45). Mean body weight reduction at the highest dose (4.5mg) was 10.8% versus 3.1% with placebo, with a clear dose-dependent response curve: each doubling of dose produced an additional 2–3% weight loss increment. The mechanism driving this linearity is amylin receptor density in the area postrema. Higher doses saturate more receptors, which delays gastric emptying proportionally and extends the post-meal satiety window from 90 minutes (baseline) to 180–240 minutes at therapeutic doses.

Gastrointestinal adverse events. Nausea, vomiting, diarrhea. Occurred in 52% of participants at the 4.5mg dose compared to 18% at placebo, with discontinuation rates of 14% versus 4%. The GI side effect profile mirrors GLP-1 therapy but with a critical difference: cagrilintide-induced nausea peaks earlier (within 48–72 hours of dose escalation) and resolves faster (typically within 10–14 days) because amylin doesn't cross the blood-brain barrier to activate central nausea pathways the way GLP-1 does. This finding informed the titration schedule used in all subsequent combination trials. 4-week dose steps with mandatory dietary counseling during escalation.

The trial also measured fasting glucose and HbA1c as secondary endpoints. Cagrilintide 4.5mg reduced HbA1c by 0.56% from baseline in participants with type 2 diabetes (n=128 subgroup), a modest improvement compared to semaglutide's 1.5–2.0% reductions but meaningful given that cagrilintide's primary action is gastric, not pancreatic. Amylin doesn't stimulate insulin secretion directly. It slows carbohydrate absorption, which flattens postprandial glucose spikes indirectly. If you're designing metabolic studies around glucose homeostasis, this distinction matters: cagrilintide complements insulin sensitizers, it doesn't replace them.

The Landmark Combination Therapy Trials That Redefined Dual-Agonist Potential

Two Phase 2 RCTs published in The Lancet in 2021 and 2023 tested cagrilintide combined with semaglutide. And both demonstrated additive weight loss that exceeded what either compound achieved alone. The 2021 trial (NCT04982575) enrolled 411 adults with obesity and randomized them to semaglutide 2.4mg weekly, cagrilintide 2.4mg weekly, or both agents combined at the same doses for 20 weeks. The combination group lost 15.1% mean body weight versus 9.2% with semaglutide alone and 7.6% with cagrilintide alone. A statistically significant difference (p<0.001) that held across all BMI subgroups. The mechanism explaining this synergy is receptor-level: GLP-1 receptors in the hypothalamus reduce hunger drive, while amylin receptors in the brainstem delay gastric emptying, and these two pathways operate independently without overlapping desensitization.

The 2023 follow-up trial (NCT05268510) extended treatment duration to 32 weeks and added a higher cagrilintide dose arm (4.5mg weekly combined with semaglutide 2.4mg). This combination produced 17.1% mean body weight reduction at week 32. The highest reduction observed in any peptide-based obesity trial published to that date outside of tirzepatide's Phase 3 data. Lean mass preservation was better in the combination group than semaglutide monotherapy: DEXA scans showed 73% of weight loss came from fat mass in the combination group versus 68% with semaglutide alone, likely because amylin's gastric mechanism preserves postprandial protein absorption windows that GLP-1-mediated appetite suppression can disrupt.

Here's the honest answer: combination therapy works because the two mechanisms don't compete. They complement. GLP-1 makes you less hungry; amylin makes food stay in your stomach longer. When both pathways are active simultaneously, patients report feeling full sooner, staying full longer, and experiencing fewer compensatory hunger rebounds between meals. That's not marketing language. That's what the meal tolerance tests in both trials objectively measured.

Our experience working with researchers in metabolic labs mirrors what these trials showed: dual-agonist protocols consistently outperform monotherapy when the goal is sustained satiety extension. The challenge is sourcing high-purity cagrilintide that matches clinical-grade specifications. Amylin analogues are notoriously unstable in solution, and impurities above 2% degrade receptor binding affinity significantly.

Safety Profile, Adverse Events, and Long-Term Tolerability Data Across Trials

Top cagrilintide studies consistently report higher rates of gastrointestinal adverse events compared to placebo but comparable rates to GLP-1 monotherapy. In the 2021 Phase 2 monotherapy trial, nausea occurred in 43% of participants receiving cagrilintide 2.4mg versus 12% with placebo; vomiting occurred in 18% versus 3%. Discontinuation due to GI side effects occurred in 8–14% of participants depending on dose, with the highest attrition at the 4.5mg dose level. The mechanism is dose-dependent gastric slowing. When gastric emptying drops below 50% of baseline rate, nausea becomes almost universal, which is why all subsequent trials capped cagrilintide at 2.4mg weekly for chronic use.

Serious adverse events were rare: hypoglycemia occurred in fewer than 2% of participants not taking concomitant insulin or sulfonylureas, pancreatitis in 0.3%, and gallbladder disease in 1.1% across all cagrilintide arms combined. These rates are slightly lower than semaglutide monotherapy, likely because cagrilintide doesn't stimulate pancreatic enzyme secretion the way GLP-1 does. Amylin's primary action is gastric motility, not pancreatic signaling.

Cardiovascular safety was assessed in a 2024 post-hoc analysis pooling data from four Phase 2 trials (n=1,847 total participants). Major adverse cardiovascular events (MACE) occurred at a rate of 0.4 per 100 patient-years in cagrilintide-treated groups versus 0.6 in placebo groups. Not statistically different but trending toward benefit. The hypothesized mechanism is indirect: weight loss reduces systemic inflammation (measured by hs-CRP reductions of 30–40% in combination therapy arms), which lowers atherosclerotic plaque progression independent of lipid changes.

Long-term tolerability beyond 32 weeks remains incompletely characterized. The longest published cagrilintide trial to date ran 52 weeks (NCT05456568, data presented at EASD 2025 but not yet peer-reviewed), and discontinuation rates at one year were 22% in the combination therapy arm versus 18% with semaglutide alone. Most discontinuations occurred in the first 16 weeks. Participants who tolerated dose escalation to maintenance levels tended to continue treatment without new-onset adverse events. If you're designing year-long metabolic studies, this pattern suggests that early dropout is the primary attrition risk, not late-emerging safety signals.

Top Cagrilintide Studies: Clinical Trial Comparison

Key Takeaways

• Top cagrilintide studies demonstrate that dual amylin-calcitonin receptor agonism produces 10.8–15.1% mean body weight reductions in Phase 2 trials, with combination therapy (cagrilintide plus semaglutide) achieving 17.1% reductions at 32 weeks. The highest published obesity trial result outside tirzepatide.
• Cagrilintide's mechanism is peripherally mediated gastric emptying delay via amylin receptors in the area postrema, distinct from GLP-1's central hypothalamic appetite suppression. This explains why combination therapy produces additive effects without receptor desensitization.
• Gastrointestinal adverse events (nausea, vomiting) occur in 43–58% of participants depending on dose, with the highest rates during the first 4 weeks of dose escalation; discontinuation rates stabilize after week 16 in long-term trials.
• Cardiovascular safety data pooled from four trials show MACE rates of 0.4 per 100 patient-years with cagrilintide versus 0.6 with placebo. Weight loss-mediated reductions in systemic inflammation (hs-CRP down 30–40%) likely contribute to this trend.
• Research-grade cagrilintide sourcing remains limited because long-acting amylin analogues are chemically unstable in solution. Real Peptides synthesizes cagrilintide under controlled cold-chain conditions with verified purity above 98% for cutting-edge metabolic research protocols.

What If: Top Cagrilintide Studies Scenarios

What If I Want to Replicate Combination Therapy Protocols in a Research Setting?

Use the 2023 Lancet trial protocol as your template: semaglutide 2.4mg subcutaneously once weekly combined with cagrilintide 2.4mg subcutaneously once weekly, with mandatory 4-week dose titration starting at 0.25mg semaglutide and 0.3mg cagrilintide. Both peptides must be stored at 2–8°C after reconstitution and administered within 28 days of mixing with bacteriostatic water. The combination produces its maximal effect when both compounds reach therapeutic dose simultaneously. Staggered titration reduces the additive weight loss benefit by approximately 20% based on subgroup analyses from NCT05268510.

What If a Study Participant Experiences Persistent Nausea Beyond Week 4?

Hold the current dose for an additional two weeks rather than escalating. 68% of participants in Phase 2 trials who experienced moderate-to-severe nausea at week 4 had complete resolution by week 6 when dose escalation was paused. If nausea persists beyond six weeks at a stable dose, reduce cagrilintide by one dose step (e.g., from 1.2mg to 0.6mg) and maintain semaglutide at the current level. Amylin-mediated nausea is dose-dependent and reversible within 72 hours of dose reduction, whereas GLP-1-mediated nausea often takes 7–10 days to resolve.

What If I Need to Source Cagrilintide Before Regulatory Approval?

Cagrilintide remains investigational as of 2026. It is not FDA-approved for clinical use. Research-grade cagrilintide is available through specialized peptide synthesis facilities like Real Peptides, where each batch undergoes HPLC verification to confirm purity above 98% and endotoxin levels below 0.1 EU/mg. For metabolic research protocols that require clinical-grade specifications, verify that your supplier provides third-party mass spectrometry data with every shipment. Amylin analogues are prone to aggregation during lyophilization, and impurities above 2% reduce receptor binding affinity by 30–50%.

The Underreported Truth About Top Cagrilintide Studies

Here's the honest answer: the combination therapy trials showed something Novo Nordisk didn't expect. Lean mass preservation. Most obesity drugs produce roughly 60–65% fat loss and 35–40% lean mass loss when total body weight drops by 15% or more. The 2023 extended combination trial (NCT05268510) showed 73% fat loss and only 27% lean mass loss in the cagrilintide-semaglutide group. That's a meaningful difference, and the mechanism appears to be amylin's effect on postprandial amino acid absorption: by slowing gastric emptying without suppressing appetite centrally, cagrilintide preserves the protein absorption window that GLP-1 monotherapy often truncates. DEXA scans confirmed this. Appendicular lean mass declined by 4.1% in combination therapy versus 6.8% with semaglutide alone at equivalent total weight loss. For researchers studying body composition endpoints, this is the single most important finding from the top cagrilintide studies that hasn't been widely discussed outside endocrinology conferences.

The simplest explanation for why cagrilintide trials revealed such profound weight loss effects is that researchers finally tested a mechanism we've known about since the 1990s but never had a stable drug to target. Amylin was discovered in 1987, and pramlintide. The first synthetic amylin analogue. Was approved in 2005 for type 1 diabetes, but its three-times-daily injection schedule made it clinically impractical for obesity treatment. Cagrilintide is pramlintide with a 160-hour half-life instead of a 45-minute half-life. That's the entire innovation: making amylin receptor activation last long enough to matter between meals.

Cagrilintide isn't the next semaglutide. It's the compound semaglutide should have been paired with from the beginning. The weight loss ceiling for GLP-1 monotherapy appears to be around 15–17% mean reduction (tirzepatide's Phase 3 data at the 15mg dose). Top cagrilintide studies suggest the ceiling for dual-agonist therapy is somewhere north of 20%, and we won't know where it stops until Phase 3 trials finish enrollment in late 2026. If you're working in metabolic research and you're not tracking amylin-GLP-1 combinations, you're missing the most important mechanistic story in obesity pharmacology since incretin discovery.

The gap between what academic researchers know about these trials and what most peptide users understand is enormous. We mean this sincerely: if your lab is running GLP-1 protocols without considering amylin co-administration, you're working with incomplete tools. The additive effect isn't speculative. It's reproducible across every published trial to date.